PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
295.9K views | +0 today
Follow

UK will build the world’s first fully-automated drug discovery facility expected to speed up production manyfold #pharma #digitalhealth

From www.cityam.com

Business secretary Greg Clark announced today that the UK will build the world's first fully-automated drug discovery facility.
No comment yet.

Roche acquires cancer genetics company Foundation Medicine #esante #hcsmeufr #pharma #digitalhealth

From www.businessinsider.com

Roche on Tuesday bought the rest of Foundation Medicine, a company that collects genetic data from samples of cancer tissue or blood, for $2.4 billion. Roche had held a majority stake in the company, and the deal values Foundation at $5.3 billion.
No comment yet.

Deloitte integrates patient engagement platform with Apple frameworks

From medcitynews.com

Deloitte has integrated its ConvergeHEALTH Patient Connect tool, a patient engagement platform, with Apple HealthKit, CareKit and ResearchKit.

Deloitte’s life sciences clients use Patient Connect to support their patients with diseases like diabetes and cancer.

Via email, Brett Davis, ConvergeHEALTH general manager and principal at Deloitte, discussed the industry’s shift to patient-centered care. The movement traditionally wasn’t possible from a data perspective, as consumers weren’t given power over their own data. But that’s changing because of the work of Apple and other vendors, he noted.

“As part of the Apple enterprise alliance we announced in 2016, we created a first-of-its-kind Apple practice to focus on transforming industries,” Davis said.

Initially announced in the fall of 2016, the practice includes a group of app developers who focus on healthcare-specific apps.

No comment yet.

Ready or Not, Changes Are Coming to Legacy Device Requirements in the EU

From www.mddionline.com

By 2020, new medical device products distributed within Europe must comply with the new European Medical Device Regulation. Is your company ready?
No comment yet.

50 Examples of Corporations That Failed to Innovate #digitalhealth #transfonum

From valuer.ai

Change is inevitable and innovation is no different. A lot of companies that experience innovation success, grab onto it and believe that it’s their secret to an everlasting success. So here are 50 examples of corporations that failed to innovate that you can learn from.
No comment yet.

e-Health : Comment faire de l'offre actuelle une réalité économique?  @techtomed #hcsmeufr #esante #startup #pharma

From mailchi.mp

Après avoir été au CES, à Vivatech, à la healthcare week... je reste convaincu que la vision que nous avons sur la santé de demain est la bonne... je constate que l'offre explose en e-santé.. pour autant nous sommes encore loin d'en faire une réalité pour les pro de santé, les patients, les systèmes de santé... que manque-t-il ? du temps? de l'argent? ..ou bien est-ce quelque chose d'autre? je vous propose d'en parler ensemble...de partager nos points de vue sur cette question...venez nombreux !

Lionel Reichardt / le Pharmageek:

Après avoir été au CES, à Vivatech, à la healthcare week... je reste convaincu que la vision que nous avons sur la santé de demain est la bonne... je constate que l'offre explose en e-santé.. pour autant nous sommes encore loin d'en faire une réalité pour les pro de santé, les patients, les systèmes de santé... que manque-t-il ? du temps? de l'argent? ..ou bien est-ce quelque chose d'autre? je vous propose d'en parler ensemble...de partager nos points de vue sur cette question...venez nombreux !

No comment yet.

Global Capital Confidence Barometer | Life Sciences | 18th edition - EY - Global  #esante #hcsmeufr #digitalhealth

From www.ey.com

Life sciences executives continue their confidence in M&A, with 50% of executives planning to pursue deals in coming year. Read our latest M&A report.
No comment yet.

The Big Trends Transforming Pharma | eyeforpharma  #esante #hcsmeufr #digitalhealth

From social.eyeforpharma.com

For all the world’s afflictions, the 21st century has been a relative triumph. Since 2000 infant mortality rates have dropped by half, to 5.6m. Life expectancy has reached 71, an increase of five years, and HIV-related deaths have fallen dramatically.         From smartphones to the looming prospect of driverless cars, the lightning pace of technological progress also shows no sign of slowing down. And as tech and medicine converge, the pharmaceutical industry is at the forefront of this change.
No comment yet.

#BigData Comment l'informatique et les #données dopent l'évaluation des produits de #santé #esante #hcsmeufr 

From www.ticpharma.com

Les études en vie réelle fondées sur l'analyse de sources de données de plus en plus nombreuses, à l'aide de technologies avancées de traitement informatique, redessinent les modalités d'évaluation des médicaments et dispositifs médicaux, ont expliqué plusieurs professionnels lors d'un colloque organisé le 7 juin par l'Association française des sociétés de recherche clinique sous contrat (Afcros).
GIE_GERS's curator insight, June 18, 2:44 AM

Les études en vie réelle fondées sur l'analyse de sources de données de plus en plus nombreuses, à l'aide de technologies avancées de traitement informatique, redessinent les modalités d'évaluation des médicaments et dispositifs médicaux, ont expliqué plusieurs professionnels lors d'un colloque organisé le 7 juin par l'Association française des sociétés de recherche clinique sous contrat (Afcros).

The New Class of Digital Leaders

From www.strategy-business.com

Faced with organizational challenges, more and more companies are hiring an executive to manage their digital transformation.
No comment yet.

Novartis VP: Digital therapeutics, like pills, are just another kind of treatment  #digitalhealth #esante #hcsmeufr

From www.mobihealthnews.com

A drug no longer needs to be a tangible object, according to panelist at the BIO 2018 convention in Boston. The way the pharma industry looks at medication is evolving and may be including new tech-focused treatments, such as digital therapeutics.
No comment yet.

Why doctor’s offices still use fax machines.  #digitalhealth #esante #hcsmeufr

From slate.com

Depending on whom you ask, it’s a symptom of regulations, technological limitations, financial disincentives, or good old-fashioned mulishness.
No comment yet.

Using Digital Health Technology to Better Generate Evidence and Deliver Evidence-Based Care #digitalhealth #esante #hcsmeufr

From www.onlinejacc.org

![Figure][1]



As we enter the information age of health care, digital health technologies offer significant opportunities to optimize both clinical care delivery and clinical research. Despite their potential, the use of such information technologies in clinical care and research faces major data quality, privacy, and regulatory concerns. In hopes of addressing both the promise and challenges facing digital health technologies in the transformation of health care, we convened a think tank meeting with academic, industry, and regulatory representatives in December 2016 in Washington, DC. In this paper, we summarize the proceedings of the think tank meeting and aim to delineate a framework for appropriately using digital health technologies in healthcare delivery and research.

[1]: pending:yes
No comment yet.

L'IA pour relancer l'industrie pharmaceutique

From plus.lapresse.ca

Plombée il y a une dizaine d’années par la fermeture successive d’importants centres de recherche, l’industrie québécoise des sciences de la vie est « à l’aube d’un nouveau cycle 
No comment yet.

Carrefour s'allie à Google pour son virage numérique - 

From fr.fashionnetwork.com

Actualité distribution : Google et Carrefour ont annoncé lundi un partenariat dans le numérique qui permettra notamment d'utiliser à partir de 2019 l'assistant vocal du géant américain pour commander ses achats chez le distributeur français. (#986464)
No comment yet.

Pharma giants are betting billions on gene therapies that could fundamentally change how we treat diseases

From www.businessinsider.fr

BI PRIME: Recent M&A transactions like Novartis' $8.7 billion acquisition of AveXis show that big pharma is betting big on gene therapy, a new way of treating previously untreatable diseases.
No comment yet.

Want to score on social, pharma? Follow Sanofi's lead, experts say | FiercePharma

From www.fiercepharma.com

 

Sanofi could have just let it go. When actress Roseanne Barr blamed its sleep aid Ambien for a racist post, the pharma company could have simply ignored it and let the Twitterverse call out the inaccuracy. Instead, Sanofi seized the moment and responded with a pithy, yet relevant and product-accurate tweet response that wryly noted: “While all pharmaceutical treatments have side effects, racism is not a known side effect of any Sanofi medication.”

That sort of real-time social media response isn't easy to pull off effectively. Consumer brands like Moon Pie, Wendy's and Oreo do it regularly, but there are also plenty of big brand social media flops to make companies think twice about going for the clever retort.

 

Which makes Sanofi’s leap even more significant: It's a regulated pharma company that has to send its messaging through compliance reviews. But Sanofi’s U.S. communication team moved fast enough to write, vet and post the response within hours of the original tweet, stepping into the cultural conversation as it happened.

 
 

Social media experts applauded and consumers responded—the post has been retweeted 68,800 times and liked by 186,000 accounts. It also garnered more than 6,100 comments with many people replying  “thank you,” “well done” or posting congratulatory memes. The previous top performing post from @SanofiUS garnered 78 retweets and 241 likes.

 

Pharma marketing insiders, meanwhile, praised Sanofi for its message, timing and boost to pharma social media credibility overall.

Julie Hurvitz Aliaga, vice president of social media at CMI/Compas said via email, “They tackled it before it had an opportunity to be an issue, educated about their drug and what it does not do, and won praise for doing so—as being a company who is not going to sit back and watch—but take action to educate.”

The balance of humor and seriousness was important, noted Klick Health’s senior director of social practice Brad Einarsen in a blog post: “The dry wit that infuses the tweet itself is fantastically balanced. There are many very serious issues surrounding these events, and we cannot lose sight of that, but the understated facts really pull off the corporate message and provide just the right amount of spark for others on Twitter to carry it along.”

 

RELATED: Pharma's social media strategies are growing up—and working better, too, report finds

Wendy Blackburn, vice president at healthcare and pharma agency Intouch Solutions, added her own kudos and hope for the industry: “Good for Sanofi for standing up and speaking out. I applaud their ability to react with swift action. Done the right way, we’d all like to see more of this from pharma.”

For pharma companies that might be interested in doing that, she offered a few tips. Companies should listen especially for well-known people or celebrity mentions of their brands because whether positive or negative, those get a lot of attention on social media. She also advised setting up an action plan so that the company can act quickly in those moments. And finally, just do it.

“Respond as immediately as possible. Current events move too quickly. Tomorrow is too late,” Blackburn said.

 
No comment yet.

ePharma 2018: Ann Handley Interview

From www.youtube.com

Ann Handley, Marketing Profs, Founder & CEO, discusses how Pharma can be 'Bigger, Braver, Bolder' in its marketing strategies at the annual ePharm
Art Jones's curator insight, June 11, 3:57 PM

Key take-away: Always produce marketing content using the context. This can only occur when you know the ideal customers narrative almost as they know it.

 

Do the work!

Pharma enthusiastic for digital medicine, but some roadblocks remain  #esante #hcsmeufr #digitalhealth

From www.mobihealthnews.com

Stakeholders across healthcare are beginning to weigh the benefits and challenges digital therapeutics could bring to their businesses, and pharma is no exception. During an afternoon roundtable session held Wednesday at BIO 2018 in Boston, a panel of digital medicine and pharmaceutical representatives discussed the impact that these novel medicines has had, and could have, on drugmakers, regulators, and those prescribing the medications.
No comment yet.

How AI Will Reshape the #Pharma Industry and Make Marketing Easier Than Ever –  #esante #hcsmeufr #digitalhealth

From www.pm360online.com

Medicine revolves around quality of and access to care. For the pharmaceutical industry, that means delivering the right information and pharmaceutical response to those who need it. Often, that response has been via a doctor’s prescription pad driven from broadly targeted ads on TV or in magazines.

With the help of AI, the pharmaceutical industry will soon be able to proactively and promptly reach out to sufferers to provide a streamlined, personalized treatment experience. That’s just the beginning. AI will also shape R&D, front-line responses, and marketing, just to name a few.

Supported by new insights from AI, the pharma industry of the near future will increasingly take an outcomes-based approach, centered around the “true customer experience”—drawing on the successes of other industries with highly advanced customer experience management. Plus, with new AI research targets that include genomics, proteomics, and DNA sequences, the new pharma landscape will be a patient-centered world where medicine comes to the individual rather than the other way around. “The Patient Will See You Now” will become the new normal.

Let’s take a look at some examples of how AI will help make this vision a reality.

Real-time Monitoring and Outreach

Pharma is well-known for its substantial marketing spend. And yet, as an industry it’s relatively taciturn on social media and with other online discussions. Listening is a different matter. A huge amount of personal medical information is voluntarily shared online through social media networks, ailment-specific forums, and more.

What used to happen on open communities—“public” spaces owned and overseen by companies or organizations—is now taking place on virtual communities. These are adaptive, community-run spaces that are self-owned and self-governed, and which may span multiple networks or domains.

Being able to reach into these spaces, whether public or private, represents a huge opportunity for the pharma of tomorrow. Using AI for real-time social listening, the pharma industry will be able to monitor, identify, and add value to conversations around specific ailments, treatments, and drugs. Say, for example, a patient is suffering from IBS but is unhappy with the current formulation of their medication—specifically how it interacts with medication being taken for a thyroid condition.

An AI can recognize that this patient suffers from two separate conditions and is unhappy with their current formulation. It can then be programmed to reach out to the patient with advice about contacting their doctor about a different formulation or treatment, pointing to a centralized resource.

This same approach can be used to gather information more generally in order to gauge patient satisfaction, issues around a condition, and the market. This can in turn help inform marketing and R&D.

Countering Knowledge Gaps and Bias

Medicine draws upon a knowledge base that we know to be imperfect. Note the known issues in diagnosing heart attacks in women vs. men. Similarly, autoimmune conditions, more common in women than men, have been underdiagnosed or have historically taken a long time to pinpoint and treat. Much of this is due to gaps in clinical data, or biases that have focused on particular groups for particular types of illnesses. Proper, uncolored listening can help shift away from these biases by taking a larger and more comprehensive snapshot of patient data. It can also be used to monitor, identify, and track community sentiment around particular drugs, clinicians, and outcomes.

Using AI to monitor, parse, and understand voluntarily shared information on message boards, health apps, or social media will identify gaps and biases in clinical data or understanding. This knowledge can then be used to direct subsequent studies, marketing outreach, or novel formulations. AI can also be used to create cohorts of patients for enrollment in trials, reducing enrollment time and associated costs, and speeding up the process of getting essential treatments into the hands of sick patients.

This represents a significant benefit not just for those groups who have been traditionally underserved by medicine, but also for pharma companies for whom new R&D and marketing opportunities will open up.

Beware! One very, very common misconception is that an AI is like Spock from Star Trek—a being of perfect logic, uninterested in such petty things as prejudice or systemic social bias. Sadly, AIs are taught based on real-world data, and we’ve seen again and again that this data is biased because society is biased. However, there are some interesting efforts to produce more transparent machine learning processes (if you’re interested, please check out the Fairness, Accountability, and Transparency in Machine Learning group).

The New Frontline of Medicine

The way patients engage with healthcare is changing. Dispersed populations, changes in healthcare provision, and a shift towards digital interfaces mean that an RN or family doctor are unlikely to be at the front lines of healthcare in years to come. Convenient and accessible, computers will become the fundamental tool for triage and basic diagnosis.

Under the umbrella of “telemedicine” or “telehealth,” this approach involves the remote provision of real-time medical or well-being services respectively. Using technology and AI in tandem, it seeks to improve the patient experience by delivering on-demand care online and in as seamless a manner as possible.

Imagine chatbots that are able to function as that front line of care. Whether installed on condition-specific sites or forums, or written into the websites of clinics or insurance providers, they’ll be programmed to conduct a basic back-and-forth exchange exploring an individual’s condition and alternatives to treatment. These can complement or even in some instances replace the need to see clinical staff—although to what extent remains to be seen.

As such AI will help take the pressure off front-line staff, while also delivering valuable information about treatment. There is, of course, the need to not be seriously irritating—nobody loves a phone menu where they are stuck in “press 9 to repeat these options,” and chatbots can suffer from the same flaws.

Improved Healthcare Experiences

In healthcare, empathy is key. As AI grows more sophisticated and nuanced, it will give pharmaceutical companies insight into how patients talk about their conditions, treatments, and formulations. This awareness will allow pharma companies to tailor their tonality, topics, and timing to resonate with the needs and expectations of patients.

Moreover, AI will be used to collect and analyze written data in both public and private forums to gauge patient—and practitioner—experience with the healthcare system more generally. These genuine, candid responses will help shape the future delivery of healthcare and ensure better outcomes for all.

The healthcare industry is already monitoring and analyzing patient and practitioner perspectives through surveys and influencer feedback. But with AI’s support, these efforts can scale up, and shift from the general to the granular. In a few years’ time, AI will make pharma marketers’ jobs easier and more streamlined—and patients will benefit too.

No comment yet.

Une université américaine a développé un "Google Maps" : Un outil de datavisualisation pour mieux voir les principes actifs des #médicaments #BigData #hcsmeufr #Esante

From www.sciencesetavenir.fr

Un outil de datavisualisation pour mieux voir les principes actifs des médicaments

L'Université de Caroline du Nord a développé un outil web permettant de visualiser en 3D la proximité des molécules en chimie, et plus particulièrement pour les substances actives des médicaments. Explications.

GIE_GERS's curator insight, June 5, 11:59 AM
Un outil de datavisualisation pour mieux voir les principes actifs des médicaments

 

L'Université de Caroline du Nord a développé un outil web permettant de visualiser en 3D la proximité des molécules en chimie, et plus particulièrement pour les substances actives des médicaments. Explications.